Based in the SOMA and San Diego offices, Mike Hostetler provides strategic IP counseling to growth enterprises in the pharmaceutical and biotechnology, and information technology industries.

Dan Koeppen is a corporate and securities partner in the firm's San Diego office. Dan specializes in corporate governance, mergers and acquisitions, public offerings, and venture capital financings. He has extensive experience representing public and private life science and technology companies in a wide range of sectors, including biotechnology, consumer products, data security, medical device, pharmaceutical, semiconductor, software, and social media, through all stages of their growth from start-up to mature public companies. In addition, Dan represents leading investment banks in their underwriting transactions, and regularly advises numerous venture capital firms and corporate strategic investors in connection with their investments in emerging growth companies.

Michelle Hale focuses on complex, government-facing antitrust matters. Michelle regularly represents companies before the Federal Trade Commission (FTC) and the U.S. Department of Justice in conduct and merger investigations, including specializing in matters involving investigations into potential Robinson-Patman Act violations. This experience informs her ability to provide effective antitrust counseling on a wide range of business conduct, including joint ventures, collaborations, and pricing and distribution, among others. She also has extensive experience navigating through the complexities of the U.S. HSR and multi-jurisdictional filing processes.

Matt represents companies in antitrust matters, including M&A clearance.

Deborah Smith is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati. She assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology.

Phillip (Phil) McGill is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he represents clients on corporate and securities law matters in the life sciences and technology sectors. His practice is focused on being a strategic partner to companies throughout each phase of the corporate life cycle, with an emphasis on guiding companies through late-stage financings and exits, as well as post-IPO public company representation. He has particular expertise collaborating with venture capital firms and universities as counsel to companies formed through their discovery engine and incubator programs.

Michelle advises companies on executive compensation and employee benefits matters.